Market analysts’ consensus outlook for next year seems relatively subdued, with earnings continuing to flop around in the negative territory, reaching -US$10.67M in 2019. Moreover, earnings should fall further in the following year, declining to -US$12.55M in 2020 and -US$15.89M in 2021.
While it’s helpful to understand the growth rate year by year relative to today’s figure, it may be more insightful to evaluate the rate at which the business is moving on average every year. The advantage of this method is that it ignores near term flucuations and accounts for the overarching direction of Atossa Genetics’s earnings trajectory over time, fluctuate up and down. To calculate this rate, I’ve inserted a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is 25.97%. This means that, we can assume Atossa Genetics will grow its earnings by 25.97% every year for the next few years.
For Atossa Genetics, I’ve put together three pertinent aspects you should further research:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Valuation: What is ATOS worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether ATOS is currently mispriced by the market.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of ATOS? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!